Smallpox Clinical Trial
— BCV-001Official title:
A Phase 1, Open-label, Single-dose, Randomized, Two-period, Crossover Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adult Participants
Verified date | April 2024 |
Source | Emergent BioSolutions |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this clinical trial is to evaluate whether both Form H and Form II, 100mg brincidofovir tablets are bioequivalent, when given under fasting conditions in healthy adults. Participants will be randomized to each receive one tablet of Form H and one tablet of Form II,14 days apart and undergo pharmacokinetic testing pre-dose and post-dose to evaluate safety. This is an open-label, single-dose, randomized, two-period, crossover study.
Status | Completed |
Enrollment | 44 |
Est. completion date | September 27, 2023 |
Est. primary completion date | August 14, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - Able and willing to provide informed consent voluntarily signed by participant. - Male or female between 18 to 70 years of age, inclusive at screening. - Body mass index (BMI) from 18 to 32 kg/m² with a minimum body weight of = 50 kg, inclusive at screening. - Women must be of nonchildbearing potential, i.e., postmenopausal woman (defined as spontaneous amenorrhea for 1-year prior to Period 1 Day 1) with a confirmed follicle stimulating hormone (FSH) level in laboratory's "postmenopausal" reference range; or a premenopausal woman documented as surgically sterile following either a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy, tubal ligation. - Males must be surgically sterilized (confirmed by documented azoospermia at least 90 days after procedure). - Overtly healthy as determined by medical evaluation and judgment of the investigator including medical history, physical examination (PE), laboratory tests, vital signs (VS), and eletrocardiogram (ECG) at screening and Day -1. [Note: hematology, serum chemistry, and urinalysis parameters must fall within the laboratory's normal reference ranges or have been determined by the investigator to have no clinical significance in the context of this study.] Except: 1. Alanine transaminase (ALT), aspartate aminotransferase (AST) and gammaglutamyl transferase (GGT) x =1.5 upper limit of normal reference range (ULN) 2. Total Bilirubin x =1.5 ULN 3. Hemoglobin (Hb) =10.5 g/dL for females or =12 g/dL for males - Able to comply with the dosing instructions and available to complete the study schedule of assessments. Exclusion Criteria: - History or current symptoms of any serious psychiatric illness, including addiction, which could interfere with participant treatment, assessment, or compliance with the protocol. - History of chronic liver disease or hepatic impairment, including but not limited to alcoholic liver disease, chronic viral hepatitis, autoimmune hepatitis, steatosis, or hemochromatosis. Note: A remote (=12 months prior to screening) history of hepatitis A infection will not be cause for exclusion. - History of Gilbert's syndrome or current evidence of the disease based on laboratory information at screening visit or Day -1. - History of hematological disorders, including disorders such as a bleeding disorder or a risk of gastrointestinal bleeding. - Clinically significant history of difficulty with blood donation, including vasovagal syncope (fainting), and/or poor venous access for the purposes of phlebotomy. - Positive (reactive) serological test result at the screening evaluation consistent with possible infection with Hepatitis B virus (HBV), Hepatitis C virus (HCV), or Human immunodeficiency virus type 1 or 2 (HIV). - Positive test for drugs of abuse and/or alcohol at either screening or check-in days. - Clinically significant infection (e.g., COVID-19, cold, flu, or febrile illness) within 14 days prior to Period 1 Day 1. - Donated a unit of blood or had clinically significant blood loss within 30 days prior to Period 1 Day 1 or donated plasma within 14 days prior to Period 1 Day 1. - Received any investigational drug, agent, or device within 30 days prior to Period 1 Day 1, or current participation in another interventional study. - Consumed any fruit juice including grapefruit juice, pomegranate juice, cranberry juice, orange juice, and Seville orange juice (also known as sour, bitter or bigarade orange) within 3 days prior to Period 1 Day 1 and throughout the study, unless prior approval is granted by both the investigator and the medical monitor. - Received any medication or herbal product (e.g., St. John's wort) known to induce or inhibit hepatic metabolizing enzymes and/or transporters within 30 days or 5 half-lives of the compound, whichever is longer, prior to Period 1 Day 1 and throughout the study, unless approval is granted by both the investigator and the medical monitor. - Received any vaccines (including COVID-19 vaccine) within 14 days prior to Period 1 Day 1 and throughout the study, unless approval is granted by both the investigator and the medical monitor. - Any condition or set of circumstances that, in the judgment of the investigator, could interfere with the participant's ability to comply with the dosing schedule and completion of the study evaluations (e.g., participants who are unable to communicate or cooperate with the investigator). |
Country | Name | City | State |
---|---|---|---|
United States | Altasciences | Overland Park | Kansas |
Lead Sponsor | Collaborator |
---|---|
Emergent BioSolutions |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | PK endpoint - Peak Plasma Concentration (Cmax) | Assess maximum observed plasma concentration of Brincidofovir | Through 96 hours post-dose | |
Primary | PK endpoint - AUClast | Assess area under the plasma concentration-time curve from time 0 to time of the last measurable concentration (AUC 0 - last) of Brincidofovir | Through 96 hours post-dose | |
Primary | PK endpoint - AUCinf | Assess area under the plasma concentration-time curve from time 0 to infinity (AUC 0 - inf) of Brincidofovir | Through 96 hours post-dose | |
Primary | Incidence of treatment adverse events (AEs) | Incidence of treatment-emergent AEs, treatment-related AEs, severe AEs, AEs leading to withdrawal and serious adverse events | Through end of study visit (within 14 days after 2nd dose) | |
Primary | Descriptive statistical summary abnormal Heart Rate | Descriptive statistical summary (summarized by treatment, study day, and time) of abnormal heart rate | Through end of study visit (within 14 days after 2nd dose) | |
Primary | Descriptive statistical summary abnormal Respiratory Rate | Descriptive statistical summary (summarized by treatment, study day, and time) of abnormal respiratory rate | Through end of study visit (within 14 days after 2nd dose) | |
Primary | Descriptive statistical summary abnormal Systolic Blood Pressure and Diastolic Blood Pressure (mmHg) | Descriptive statistical summary (summarized by treatment, study day, and time) of abnormal Systolic Blood Pressure | Through end of study visit (within 14 days after 2nd dose) | |
Primary | Descriptive statistical summary abnormal Body Temperature (Celsius) | Descriptive statistical summary (summarized by treatment, study day, and time) of abnormal body temperature | Through end of study visit (within 14 days after 2nd dose) | |
Primary | Chemistry parameters: Total Protein, Albumin, Globulin (g/dL) | Descriptive statistical summary (summarized by treatment, study day, and time) of Total Protein, Albumin, Globulin | Through end of study visit (within 14 days after 2nd dose) | |
Primary | Chemistry parameter: Albumin/Globulin ratio | Descriptive statistical summary (summarized by treatment, study day, and time) of albumin/globulin ratio | Through end of study visit (within 14 days after 2nd dose) | |
Primary | Chemistry parameters: alkaline phosphatase, ALT, AST, GGT and Creatine phosphokinase (U/L) | Descriptive statistical summary (summarized by treatment, study day, and time) of alkaline phosphatase, ALT, AST, GGT and Creatine phosphokinase | Through end of study visit (within 14 days after 2nd dose) | |
Primary | Chemistry parameters: bilirubin (total and direct), BUN, serum calcium, glucose (random), serum phosphate, serum uric acid and serum magnesium (mg/dL) | Descriptive statistical summary (summarized by treatment, study day, and time) of bilirubin (total and direct), BUN, serum calcium, glucose (random), serum phosphate, serum uric acid and serum magnesium | Through end of study visit (within 14 days after 2nd dose) | |
Primary | Chemistry parameters: serum chloride, CO2, serum sodium and serum potassium (mmol/L) | Descriptive statistical summary (summarized by treatment, study day, and time) of serum chloride, CO2, serum sodium and serum potassium | Through end of study visit (within 14 days after 2nd dose) | |
Primary | Chemistry parameter: Creatinine (g/24h) | Descriptive statistical summary (summarized by treatment, study day, and time) of creatinine | Through end of study visit (within 14 days after 2nd dose) | |
Primary | Chemistry parameter: eGFR (ml/min) | Descriptive statistical summary (summarized by treatment, study day, and time) of eGFR | Through end of study visit (within 14 days after 2nd dose) | |
Primary | Chemistry parameter: LDH (units/L) | Descriptive statistical summary (summarized by treatment, study day, and time) of LDH | Through end of study visit (within 14 days after 2nd dose) | |
Primary | Hematology parameters: basophils, eosinophils, lymphocytes, monocytes and neutrophils (cells/uL) | Descriptive statistical summary (summarized by treatment, study day, and time) of basophils, eosinophils lymphocytes, monocytes and neutrophils | Through end of study visit (within 14 days after 2nd dose) | |
Primary | Hematology parameters: leukocytes and platelets (thousand/uL) | Descriptive statistical summary (summarized by treatment, study day, and time) of leukocytes and platelets | Through end of study visit (within 14 days after 2nd dose) | |
Primary | Hematology parameters: proportion of basophils, eosinophils, lymphocytes, monocytes and neutrophils | Descriptive statistical summary (summarized by treatment, study day, and time) of basophils/leukocytes, eosinophils//leukocytes, lymphocytes//leukocytes, monocytes//leukocytes and neutrophils//leukocytes | Through end of study visit (within 14 days after 2nd dose) | |
Primary | Hematology parameter: erythrocytes (million/uL) | Descriptive statistical summary (summarized by treatment, study day, and time) of erythrocytes | Through end of study visit (within 14 days after 2nd dose) | |
Primary | Hematology parameter: erythrocytes mean corpuscular volume (MCV) (fL) | Descriptive statistical summary (summarized by treatment, study day, and time) of erythrocytes MCV | Through end of study visit (within 14 days after 2nd dose) | |
Primary | Hematology parameter: hematocrit (%) | Descriptive statistical summary (summarized by treatment, study day, and time) of hematocrit | Through end of study visit (within 14 days after 2nd dose) | |
Primary | Hematology parameter: hemoglobin (g/dL) | Descriptive statistical summary (summarized by treatment, study day, and time) of hemoglobin | Through end of study visit (within 14 days after 2nd dose) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05976100 -
Study of the Safety, Tolerability, Pharmacokinetics of NIOCH-14 in Volunteers Aged 18-50 Years
|
Phase 1 | |
Completed |
NCT01540929 -
Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel
|
||
Completed |
NCT00258947 -
Evaluation of Take and Safety of a Smallpox Vaccine in Healthy Young Adults
|
Phase 2 | |
Completed |
NCT00189969 -
Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive Subjects
|
Phase 1 | |
Terminated |
NCT00053508 -
Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination
|
Phase 2 | |
Completed |
NCT01317238 -
Safety and Efficacy of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers
|
Phase 3 | |
Completed |
NCT01056770 -
Safety and Efficacy of CJ Smallpox Vaccine in Healthy Volunteers
|
Phase 3 | |
Terminated |
NCT00282581 -
Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive
|
Phase 1 | |
Withdrawn |
NCT00389103 -
Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)
|
Phase 1 | |
Completed |
NCT00998543 -
A Long-Term Study of Healthy Adults Vaccinated With One Dose of Smallpox Vaccine (LISTER Strain)
|
Phase 2 | |
Completed |
NCT00133575 -
ACAM 3000 MVA at Harvard Medical School
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00103584 -
Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Volunteers
|
Phase 1/Phase 2 | |
Completed |
NCT00050505 -
Expanded Dryvax Dilution Study in Previously Vaccinated Adults
|
Phase 2 | |
Completed |
NCT05846243 -
Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years
|
Phase 2/Phase 3 | |
Completed |
NCT00082446 -
Combination Study With MVA BN and Dryvax
|
Phase 1 | |
Completed |
NCT00038987 -
Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT
|
Phase 1/Phase 2 | |
Completed |
NCT05762523 -
Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years
|
Phase 1 | |
Completed |
NCT04971109 -
Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Day
|
Phase 3 | |
Completed |
NCT00646152 -
Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study
|
Phase 1 | |
Completed |
NCT01668537 -
A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects
|
Phase 2 |